Cargando…

The position of combined medical treatment in acromegaly

Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coopmans, Eva C., van Meyel, Sebastiaan W. F., van der Lely, Aart J, Neggers, Sebastian J. C. M. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522231/ https://www.ncbi.nlm.nih.gov/pubmed/31939490 http://dx.doi.org/10.20945/2359-3997000000195

Ejemplares similares

Approach to the Patient With Treatment-resistant Acromegaly
por: Coopmans, Eva C, et al.
Publicado: (2022)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study
por: Coopmans, Eva C, et al.
Publicado: (2021)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Soluble Klotho: a possible predictor of quality of life in acromegaly patients
por: Coopmans, Eva C., et al.
Publicado: (2020)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Towards an Earlier Diagnosis of Acromegaly and Gigantism
por: Sisco, Jill, et al.
Publicado: (2021)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

ACRODAT® and AcroVoice: an insight into a holistic approach to the management of acromegaly
por: Lundie, Mark, et al.
Publicado: (2019)

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life
por: Varewijck, A J, et al.
Publicado: (2014)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies
por: Coopmans, Eva C., et al.
Publicado: (2019)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Development of ACRODAT(®), a new software medical device to assess disease activity in patients with acromegaly
por: van der Lely, Aart J., et al.
Publicado: (2017)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study
por: Coopmans, E. C., et al.
Publicado: (2020)

ODP353 Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly
por: Culler, Michael, et al.
Publicado: (2022)

Overweight and obesity in type 1 diabetes is not associated with higher ghrelin concentrations
por: Özcan, Behiye, et al.
Publicado: (2021)

OR24-02 Identification of Membrane Proteins That Enhance the Responsiveness of the Ghrelin Receptor
por: Prins, Karina, et al.
Publicado: (2020)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states
por: Özcan, Behiye, et al.
Publicado: (2017)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer
por: Blijdorp, Karin, et al.
Publicado: (2012)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
por: Fleseriu, Maria, et al.
Publicado: (2022)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years
por: van Santen, Selveta S, et al.
Publicado: (2020)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Medical Therapy of Acromegaly
por: Plöckinger, U.
Publicado: (2012)

New Treatments for Acromegaly
por: Wass, John A H, et al.
Publicado: (1998)

Preoperative Medical Treatment for Patients With Acromegaly: Yes or No?
por: Albarel, Frederique, et al.
Publicado: (2022)

Persistent inflammation and endothelial dysfunction in patients with treated acromegaly
por: Wolters, T L C, et al.
Publicado: (2019)

Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma
por: van Santen, Selveta Sanne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i81m567opilamgfpv1p5gqnsu8